Table 2.
Laboratory data for patients with primary hypertension and the control group
| Variable | Contro group (N = 83) | PH patient group (N = 126) | p |
|---|---|---|---|
| Cholesterol (mg/dl) | 175.6 ± 39.1 | 173.6 ± 33.7 | ns |
| Triglicerydes (mg/dl) | 69 (38–312) | 84 (28–425) | 0.05 |
| HDL-cholesterol (mg/dl) | 46.6 ± 9.8 | 44.6 ± 9.6 | ns |
| TTG/HDL | 1.48 (0.64-15) | 1.84 (0.58–42) | 0.01 |
| LDL-cholesterol (mg/dl) | 111 (60–185) | 110 (43–226) | ns |
| Lp(a) (mg/dl) | 11.7 ± 7.6 | 15.5 ± 11.7 | 0.02 |
| Uric acid (mg/l) | 4.08 ± 0.63 | 5.48 ± 1.19 | <0.001 |
| Homocysteine (μmol/l) | 8.9 ± 3.4 | 10.2 ± 3.5 | 0.02 |
| hsCRP (mg/dl) | 0.44 (0.12–6.74) | 0.74 (0.02–4.68) | 0.01 |
| Fasting glucose (mg/dl) | 90 (78–105) | 85 (67–109) | 0.001 |
| Fasting insulin (mU/ml) | 9 (3.3–15) | 12.8 (3–39) | 0.001 |
| HOMA-IR | 1.9 (0.74–3.28) | 2.78 (1.11–8.77) | 0.001 |
| GPx (U/gHb) | 32.8 (20.1–42.1) | 31.5 (23.8–39.9) | 0.005 |
| GSH (μmol/l) | 792.5 (253.2–889.1) | 760.1 (441.7–889.4) | 0.001 |
| ADMA (μmol/l) | 0.46 (0.15–1.30) | 0.55 (0.25–1.45) | 0.02 |
| oxyLDL (mU/ml) | 260.9 (0.21–1272) | 400.15 (45.8–1372) | 0.008 |
| Albuminuria(mg/24 h) | n.a. | 14.7 (2–270) |
Data are presented as the mean ± SD or as the median with the range in parenthesis, as appropriate
HDL high-density lipoprotein-cholesterol, TTG total triglycerydes, LDL low-density lipoprotein-cholesterol, Lp(a) lipoprotiein a, hsCRP high-sensivity C-reactive protein, HOMA-IR homeostasis model assessment for insulin resistance, GPx glutathione peroxidase, GSH reduced glutathione, ADMA serum asymmetric dimethyloarginine, oxyLDL oxidized LDL-cholesterol, ns not significant